Compositions and methods for the prevention and treatment of rabies virus infection
AssigneeReplicate Bioscience, Inc.
InventorsNathaniel Stephen Wang, Shigeki Joseph Miyake-Stoner, Parinaz Aliahmad, Andrew Geall
Life of this patent
Estimating the term…
Abstract
The present disclosure relates generally to the field of molecular virology, and particularly relates to nucleic acid molecules encoding a modified alphavirus virus viral genome or self-replicating RNA (srRNA) construct, recombinant cells and pharmaceutical compositions containing the same, as well as the use of such nucleic acid molecules, recombinant cells and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for eliciting an immune response in a subject in need thereof, as well as methods for preventing and/or treating rabies virus infection.
Claims26
A nucleic acid construct comprising a nucleic acid sequence encoding a modified alphavirus genome or self-replicating RNA (srRNA),
- wherein the modified alphavirus genome or srRNA comprises no nucleic acid sequence encoding viral structural proteins required for viral particle formation,
- wherein the nucleic acid sequence encoding the viral structural proteins of the modified alphavirus genome or srRNA has been replaced by a coding sequence for a polypeptide construct comprising an envelope glycoprotein G of a rabies virus (RABV-G), a variant thereof, or an antigenic determinant of either thereof, and
- wherein the nucleic acid construct comprises the nucleic acid sequence of SEQ ID NO:
- 2 and SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.